Aptorum Group Limited: Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions

Related Keywords

United States ,Canada ,Singapore ,Dennis Riedl ,Clark Cheng ,Craig Brelsford ,Ghislaine Gasparetto ,Aptorum Group Form ,Aptorum Group Or ,Drug Administration ,Singapore Agency For Science ,Actifin Financial Communications Europe ,Redchip Financial Communications United States ,Daptorum Group ,Aptorum Group Limited Nasdaq ,Regulatory News ,Group Limited ,Euronext Paris ,Methicillin Resistant Staphylococcus Aureus ,Acute Bacterial Skin ,Skin Structure Infections ,Chief Medical Officer ,Executive Director ,Serious Adverse Events ,Aptorum Group Limited ,Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,Financial Communications United States ,Financial Communications Europe ,Aptorum ,Group ,Imited ,Nnounces ,Completion ,Discussions ,First ,Glass ,Mall ,Olecule ,Drug ,Targeting ,Methicillin ,Resistant ,Staphylococcus ,Laureus ,